Cyclacel cancer deal with AZN

Cyclacel (Dundee, U.K.) and AstraZeneca (AZN; LSE:AZN) will develop small molecule macromolecular substrate inhibitors against Cyclacel's CYC103 cyclin binding groove target. Cyclacel will develop pep...